Engineered immune cells take aim at autoimmune diseases
NCT ID NCT07676266
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This early-stage study is testing a new treatment called C-CAR168 for people with autoimmune diseases like multiple sclerosis, lupus, and myasthenia gravis that have not improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to target and attack faulty immune cells that cause the disease. The main goal is to check the safety of this approach and find the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- C-CAR168 (bispecific CAR-T cells targeting CD20 and BCMA)
- What this could lead to
- If successful, this could offer a new treatment option for people with severe autoimmune diseases like multiple sclerosis or lupus that have not responded to standard therapies.
- What could go wrong
- This is a very early (Phase 1) and small study (18 people), so safety and effectiveness are not yet known. CAR-T therapy can cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE-MEDIATED NECROTIZING MYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Affiliated Hospital of Qingdao University
Qingdao, Qindao, Shandong, 266003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.